title: Colchicine treatment in autosomal dominant polycystic kidney disease: many points in common.
abstract: Autosomal dominant polycystic kidney disease (ADPKD) is the most common of the inherited renal cystic diseases and constitutes 10% of the end stage kidney disease population. ADPKD is caused by PKD1 and PKD2 gene mutations in 85% and 15% of the cases respectively. Its high prevalence and negative impact on health outcomes fostered efforts to explain pathophysiologic pathways of cyst formation in kidneys. Among these are increased apoptosis, unopposed proliferation of tubule cells, impaired polarization and planar cell polarity, impaired cAMP pathway, cilier dysfunction, activated mTOR pathway, increased tumor necrosis factor-alpha (TNF-alpha) production. Many drugs have been tried in an attempt to halt cystogenesis in some point. Despite success to some extent in experimental studies, none reached clinical armamentarium yet. Colchicine, originally extracted from Colchicum autunale, is an anti-inflammatory drug that has been in continuous use for more than 3000 years. It has been used successfully to prevent attacks of familial mediterranien fever and amyloidosis, to treat gout and pseudogout attacks for a few decades. Colchicine principally is a microtubule inhibitor, thus prevents cell migration, division, and polarization. It also has anti-apoptotic, anti-proliferative and anti-inflammatory effects and down-regulates (TNF-alpha) receptors. As can easily be seen, many of the effects of colchicine have pathophysiologic counterparts in ADPKD. Thus, we hypothesized that colchicine would be beneficial to prevent or at least delay cyst formation in ADPKD patients. Indirect evidence also support our hypothesis, in which taxol and paclitaxel, other two microtubule inhibitors, were shown to delay cyst formation in experimental models of ADPKD. To our opinion, despite its narrow therapeutic index, widespread experience makes colchicine a suitable candidate for prolonged clinical use, should experimental studies show any benefit in ADPKD.
authors.affiliation: Selcuk University, Meram School of Medicine, Nephrology Department, Konya, Turkey. yalcinsolakmd@gmail.com
authors.forename: Yalcin
authors.initials: Y
authors.lastname: Solak
authors.forename: Huseyin
authors.initials: H
authors.lastname: Atalay
authors.forename: Ilker
authors.initials: I
authors.lastname: Polat
authors.forename: Zeynep
authors.initials: Z
authors.lastname: Biyik
mesh_terms: D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D003078:Colchicine / Q000008:administration & dosage*; D003079:Colchicum / Q000737:chemistry*; D006801:Humans; D007668:Kidney / Q000187:drug effects / Q000378:metabolism*; D008954:Models, Biological; D010936:Plant Extracts / Q000008:administration & dosage*; D016891:Polycystic Kidney, Autosomal Dominant / Q000188:drug therapy* / Q000378:metabolism*; D050257:Tubulin Modulators / Q000008:administration & dosage
chemical_list: D000893:Anti-Inflammatory Agents; D010936:Plant Extracts; D050257:Tubulin Modulators; D003078:Colchicine